Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.

Lymphoma Hub is a education podcast hosted by Scientific Education Support, with 53 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Scientific Education Support hosts Lymphoma Hub, a education show with 53 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Lymphoma Hub

  Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape

  Aug 20, 202623 min

  On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, led a case-based presentation and panel discussion featuring Susan O’Brien, Farrukh Awan, and Gilles Salles on optimizing chronic lymphocytic leukemia management in a changing landscape.    This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Lymphoma Hub

  Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence

  Aug 12, 202627 min

  On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas Southwestern Medical Center, Dallas, US, delivered a presentation on BTK inhibitors in practice: Treatment selection and emerging clinical evidence.  This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.    Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Lymphoma Hub

  Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs

  Aug 12, 202612 min

  On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien, University of California Irvine, US, delivered a presentation on BTK inhibitors in chronic lymphocytic leukemia: Mechanisms, clinical considerations, and unmet needs.  This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Lymphoma Hub

  EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

  Jul 21, 20268 min

  The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)?  This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.   Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes
• 

  Lymphoma Hub

  EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?

  Jul 16, 202610 min

  Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?    This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.  Hosted on Acast. See acast.com/privacy for more information.

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.